Severe asthma is associated with a loss of LX4, an endogenous anti-inflammatory compound.
about
The role of lipoxin A4 in endometrial biology and endometriosisEpithelial Anion Transport as Modulator of Chemokine SignalingResolution of Inflammation: What Controls Its Onset?Resolution of inflammation in asthmaLipoxin A4 levels in asthma: relation with disease severity and aspirin sensitivityDHA- and EPA-derived resolvins, protectins, and maresins in airway inflammationSpecialized pro-resolving mediators: endogenous regulators of infection and inflammationLeukotriene B4 levels in sputum from asthma patientsResolution of acute inflammation in the lungCorticosteroid suppression of lipoxin A4 and leukotriene B4 from alveolar macrophages in severe asthma.Airway lipoxin A4 generation and lipoxin A4 receptor expression are decreased in severe asthma.Endogenous lipid mediators in the resolution of airway inflammationResolvins: natural agonists for resolution of pulmonary inflammation.Innate immunity is a key factor for the resolution of inflammation in asthmaLipoxin generation is related to soluble epoxide hydrolase activity in severe asthmaExpression of functional leukotriene B4 receptors on human airway smooth muscle cells.Lovastatin decreases acute mucosal inflammation via 15-epi-lipoxin A4.Serum amyloid A opposes lipoxin A₄ to mediate glucocorticoid refractory lung inflammation in chronic obstructive pulmonary diseaseResolvin D1 and Resolvin E1 Promote the Resolution of Allergic Airway Inflammation via Shared and Distinct Molecular Counter-Regulatory Pathways.An investigation of the resolution of inflammation (catabasis) in COPD.Mast cells and eicosanoid mediators: a system of reciprocal paracrine and autocrine regulation.Efficacy, safety and tolerability of GSK2190915, a 5-lipoxygenase activating protein inhibitor, in adults and adolescents with persistent asthma: a randomised dose-ranging study.Uncontrolled airway inflammation in lung disease represents a defect in counter-regulatory signaling.Exhaled breath condensate eicosanoid levels associate with asthma and its severity.Safety and efficacy of montelukast as adjunctive therapy for treatment of asthma in elderly patientsDiminished lipoxin biosynthesis in severe asthma.Chemical mediators and the resolution of airway inflammationCorticosteroids inhibit anti-IgE activities of specialized proresolving mediators on B cells from asthma patients.Resolvins and protectins: natural pharmacophores for resolution biology.Lung damage and airway remodelling in severe asthma.The investigation of severe asthma to define phenotypes.Lipoxins, resolvins and protectins: new leads for the treatment of asthma.Chronic inflammatory airway diseases: the central role of the epithelium revisited.Bronchoprotective mechanisms for specialized pro-resolving mediators in the resolution of lung inflammation.Repression of TNF-alpha-induced IL-8 expression by the glucocorticoid receptor-beta involves inhibition of histone H4 acetylation.Ozone enhances diesel exhaust particles (DEP)-induced interleukin-8 (IL-8) gene expression in human airway epithelial cells through activation of nuclear factors- kappaB (NF-kappaB) and IL-6 (NF-IL6).ALX receptor ligands define a biochemical endotype for severe asthma.Pilot application of lipoxin A4 analog and lipoxin A4 receptor agonist in asthmatic children with acute episodes.An oily, sustained counter-regulatory response to TB.Pulmonary antifibrotic mechanisms aspirin-triggered lipoxin A(4) synthetic analog.
P2860
Q24564121-F081FBAD-3F32-43BD-AEC5-350C541F3AEAQ26744381-6F12D62E-656B-44E5-8557-ECEC93004D1CQ26747410-B5C31AB7-0F90-4D9F-B9F1-384684E64233Q26823724-FC939B49-81E2-42B7-B18E-633925D0A7B4Q28221900-FDCC5D05-305E-4D1B-9A95-C6A5BA7F5A0FQ28269550-8EB241EE-6BC8-41CA-B264-A10446E8E953Q28271331-0EC5D643-3970-42B7-A76F-9B0FE9528499Q28587885-6D374CC3-C062-4E23-9D40-99B84625FD9BQ28652204-59829154-2593-47FE-B960-124A6144BD93Q30435721-F8A8DF52-CC44-4090-B5F5-3AACCD85148CQ30438572-B80FA83F-235F-4ACC-9D8F-0669803B5B14Q34423359-31CB07A2-13BC-4F0E-A475-9FB7DC015FF5Q34448487-0AA1260D-A67E-48EF-A4D7-30A7C5DABFA6Q34465047-6A1058C7-90C1-4877-BFE9-222864643F2AQ34986906-ABE23C0D-B710-42D5-AE43-6206B3211C96Q34994690-FC688DBC-E8B9-463C-8CFB-FD2D2341DFF7Q35679301-3E74589B-5D4F-450B-ABD6-58B29C5E12A7Q35734988-47201C28-09BC-4B09-B914-DF2B27CE3D49Q36492325-35B87130-8338-43CE-9281-0FB68E1A1527Q36539037-9447C251-C1A7-4ADC-8FEE-87C0675F966DQ36819905-9FD35F5A-5BE8-4418-B8A2-626783C15FDDQ37066194-3F42C0B3-5DCD-43D0-919D-5B811FAD25B3Q37128222-ED8C51D0-340B-4618-B97F-C19659E30603Q37138368-C40F3FF8-FE91-4D79-9D60-151C9711958FQ37225387-855B0045-38F7-44E3-9611-8B96E101ED99Q37282577-218D3BDB-6F93-4C7E-8696-7ECC27E6CB61Q37306353-1EDBBC82-B989-4814-A293-20577A12721FQ37624373-FD641505-D84B-4953-BB45-434EF7260F9CQ37708842-842800BA-E501-4468-AB8E-DD37683FFE52Q37970841-CE0B78F4-957F-4D03-AB75-87E2E27DAA2BQ38003661-7919B28D-B19C-48DF-B39F-20A9EECB7A25Q38089177-C35948B2-3700-4DD7-9FB5-40D780A73C11Q38791607-9DA775E8-48C7-4144-98CF-747F02FB1E52Q39271007-8CC82278-4357-4749-A2BF-AF9018B96705Q39869230-20024196-C8D6-439E-9ADF-F331C07168E3Q40259515-91C6FB8F-8ACD-4F0A-8A8C-F74F1B7437F4Q41068189-6BA2C0BA-C0F8-48F5-AFD6-6B1AA5DCF2EFQ41672237-D30B519D-0E1B-403E-BAC5-8CE0DBD5E59DQ41807333-6DD4B595-0F5B-45F0-ABD3-EE428C0A8C92Q42220886-E9C4BADF-E526-4CD3-831C-ABA966BC1B1C
P2860
Severe asthma is associated with a loss of LX4, an endogenous anti-inflammatory compound.
description
2005 nî lūn-bûn
@nan
2005年の論文
@ja
2005年学术文章
@wuu
2005年学术文章
@zh
2005年学术文章
@zh-cn
2005年学术文章
@zh-hans
2005年学术文章
@zh-my
2005年学术文章
@zh-sg
2005年學術文章
@yue
2005年學術文章
@zh-hant
name
Severe asthma is associated with a loss of LX4, an endogenous anti-inflammatory compound.
@en
Severe asthma is associated with a loss of LX4, an endogenous anti-inflammatory compound.
@nl
type
label
Severe asthma is associated with a loss of LX4, an endogenous anti-inflammatory compound.
@en
Severe asthma is associated with a loss of LX4, an endogenous anti-inflammatory compound.
@nl
prefLabel
Severe asthma is associated with a loss of LX4, an endogenous anti-inflammatory compound.
@en
Severe asthma is associated with a loss of LX4, an endogenous anti-inflammatory compound.
@nl
P2093
P1476
Severe asthma is associated with a loss of LX4, an endogenous anti-inflammatory compound.
@en
P2093
Caroline Bonnans
Claude Chavis
Jean Bousquet
Martine Farce
Pascal Chanez
Philippe Godard
P356
10.1016/J.JACI.2004.09.038
P407
P577
2005-01-01T00:00:00Z